As 2026 begins, Java Burn reviews are once again climbing search results, not because of hype alone, but because ...

Placebo-adjusted mean weight loss of 16.3% (39 lbs) at 180 mg and 16.0% (37 lbs) at 240 mg at 44 weeks with no evidence of weight loss plateau in ACCESS II, demonstrating highest efficacy among oral ...

The Bachelor of Science in Data Analytics is a new interdisciplinary program designed to prepare you with the skills to collect, manage, analyze and interpret complex data. Building on foundations in ...

A monthly overview of things you need to know as an architect or aspiring architect. Unlock the full InfoQ experience by logging in! Stay updated with your favorite authors and topics, engage with ...

Wash. — Consumer advocates are warning “loyal” grocery shoppers that scanning their loyalty cards at the checkout may be trading far more than they realize for discounts and rewards: their personal ...

Spire Global has won contracts to provide the National Oceanic and Atmospheric Administration's Commercial Weather Data Program with global navigation satellite system (GNSS) radio occultation and ...

Integrating artificial intelligence into business areas, adopting global AI-based platforms, and building a robust ecosystem with technological partnerships—these were the three pillars on which ...

Loyalty programs were once designed to thank customers for sticking around. This could include perks like free coffee, airline miles, or grocery discounts in exchange for repeat business. But that ...

Store loyalty programs used to be simple: You’d get a punch card at a local sub shop, buy eight sandwiches and get your ninth for free. It felt like a transparent “thank you” for your business. But ...

Structure Therapeutics is developing a daily GLP-1 receptor pill called aleniglipron. Structure Therapeutics' stock soared toward an 18-month high in early Monday trading, after mid-stage data for its ...

Placebo-adjusted mean weight loss of 11.3% (27.3 lbs) with 120 mg dose in the 36-week Phase 2b ACCESS study with a 10.4% adverse event-related treatment discontinuation Placebo-adjusted mean weight ...